ReviewBiology direct2026
m
Review in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
5-methylcytosine (m5C) modification has emerged as a novel epigenetic modification of ribonucleic acids (RNAs), encompassing messenger RNAs (mRNAs) and non- coding RNAs, in recent years. This reversible modification, which is regulated by m5C regulators consisting of methyltransferases, demethyltransferases, and RNA-binding proteins, modulates all aspects of RNA metabolism and gene expression. Gastrointestinal (GI) cancers are prevalent malignancies with a high mortality rate globally. Accumulating evidence has indicated the significant role of m5C RNA modification in the tumorigenesis and progression of GI cancers. In this review, we provide a comprehensive overview of the functions and underlying molecular mechanisms of m5C RNA modification in RNA metabolism for the regulation of tumor biology, including cell proliferation, apoptosis, invasion/metastasis, chemoresistance, and other biological functions. Furthermore, we summarize the specific role of m5C modification in GI cancers and propose some insights regarding its application as a tumor biomarker and therapeutic target, aiming to offer a new perspective for m5C modification in GI cancer diagnosis and treatment in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.